TY - JOUR
T1 - HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
AU - Grundy, Scott M
PY - 1988/7/7
Y1 - 1988/7/7
N2 - THE recent introduction of a unique class of cholesterol-lowering drugs offers new promise for the treatment of hypercholesterolemia. These drugs are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the synthesis of cholesterol. Relatively low doses of these agents will reduce plasma cholesterol levels markedly, and in short-term studies, they have not been found to produce serious side effects. Thus, in 1987 the Food and Drug Administration approved one HMG-CoA reductase inhibitor — lovastatin. If reductase inhibitors prove to be free of long-term adverse effects, they will undoubtedly be used widely for treating hypercholesterolemia. This review will examine.
AB - THE recent introduction of a unique class of cholesterol-lowering drugs offers new promise for the treatment of hypercholesterolemia. These drugs are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the synthesis of cholesterol. Relatively low doses of these agents will reduce plasma cholesterol levels markedly, and in short-term studies, they have not been found to produce serious side effects. Thus, in 1987 the Food and Drug Administration approved one HMG-CoA reductase inhibitor — lovastatin. If reductase inhibitors prove to be free of long-term adverse effects, they will undoubtedly be used widely for treating hypercholesterolemia. This review will examine.
UR - http://www.scopus.com/inward/record.url?scp=0023876839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023876839&partnerID=8YFLogxK
U2 - 10.1056/NEJM198807073190105
DO - 10.1056/NEJM198807073190105
M3 - Review article
C2 - 3288867
AN - SCOPUS:0023876839
SN - 0028-4793
VL - 319
SP - 24
EP - 33
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 1
ER -